Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?

J Clin Oncol. 2011 Apr 1;29(10):e262-5. doi: 10.1200/JCO.2010.32.0242. Epub 2011 Jan 10.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / enzymology
  • Adenocarcinoma / secondary
  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Biopsy
  • Colectomy
  • Colorectal Neoplasms / diagnosis
  • Colorectal Neoplasms / enzymology
  • Colorectal Neoplasms / pathology*
  • Colorectal Neoplasms / surgery
  • DNA Modification Methylases / analysis*
  • DNA Repair Enzymes / analysis*
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Down-Regulation
  • Female
  • Humans
  • Immunohistochemistry
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / enzymology
  • Liver Neoplasms / secondary
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Precision Medicine*
  • Temozolomide
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Tumor Suppressor Proteins / analysis*

Substances

  • Antineoplastic Agents, Alkylating
  • Tumor Suppressor Proteins
  • Dacarbazine
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes
  • Temozolomide